A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT06836609
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- ALN-CIDEB — DRUGAdministered per the protocol
- Placebo — DRUGAdministered per the protocol
Study Details
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content * How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times
Key Dates
- Start date
- Apr 28, 2025
- Status verified
- Apr 2026
- Primary completion
- May 15, 2027
- Completion
- May 15, 2027
Study Design
- Enrollment
- 132 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part ARandomized per the protocol
- Experimental: Part BRandomized per the protocol
Primary Outcome Measure
Incidence of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to 48 Weeks ]
Central Contacts
- Clinical Trials Administrator844-734-6643
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona Liver Health | Chandler | Arizona | 85225 | - |
Find similar trials in Chandler, AZ
Related Studies
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASHPHASE2 · Recruiting · Boston Pharmaceuticals · Chandler, Arizona
- Assessment of Non-Invasive Testing in Major Liver-Related OutcomesEnrolling By Invitation · HRI-MAIL-NIT · Chandler, Arizona
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)PHASE3 · Recruiting · Eli Lilly and Company · Tuscaloosa, Alabama
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)PHASE2 · Recruiting · Eccogene · Chandler, Arizona